| Literature DB >> 26853128 |
Marek Jutel1, Ioana Agache2, Sergio Bonini3, A Wesley Burks4, Moises Calderon5, Walter Canonica6, Linda Cox7, Pascal Demoly8, Antony J Frew9, Robyn O'Hehir10, Jörg Kleine-Tebbe11, Antonella Muraro12, Gideon Lack13, Désirée Larenas14, Michael Levin15, Bryan L Martin16, Harald Nelson17, Ruby Pawankar18, Oliver Pfaar19, Ronald van Ree20, Hugh Sampson21, James L Sublett22, Kazunari Sugita23, George Du Toit24, Thomas Werfel25, Roy Gerth van Wijk26, Luo Zhang27, Mübeccel Akdis23, Cezmi A Akdis23.
Abstract
This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein.Entities:
Keywords: International consensus; allergen standardization; allergen vaccine; allergy; cost-effectiveness; immunotherapy; marketing authorization; mechanisms; pharmacoeconomics; regulatory authorities; tolerance; unmet needs
Mesh：
Substances：
Year: 2016 PMID： 26853128 DOI： 10.1016/j.jaci.2015.12.1300
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793